Dyadic International, Inc.
Dyadic International, Inc.
Dyadic International, Inc.
DYAI
DYAI
Nasdaq
Health Services
Medical/Nursing Services
1.19
USD
-0.02
-1.65%
Geschlossen: 07-24 20:00 (UTC+0)
1.19
USD
+0.0559
+4.70%
Nachbörslich: 07-25 00:00 (UTC+0)

DYAI Wichtige Statistiken

Hoch
1.26
Öffnen
1.21
Volumen
105.18K
Niedrig
1.12
Vorheriger Schlusskurs
1.21
Handelswert
125.54K
52W-Hoch
1.60
Rel. Volumen
0.371
Amplitude (%)
11.49%
52W-Tief
0.65
Umsatzrate
0.29%
Marktkapitalisierung
43.36M
KGV (TTM)
--
KGV (Jährlich)
--
KBV
-106.35
KUV
11.39
Gewinn je Aktie (EPS)
-0.214
Dividende (TTM)
0
Dividendenrendite
0.00%
Ausstehende Aktien
36.43M
Währung
USD

DYAI Preis-Performance

7 Tag
30 Tag
90 Tag
180 Tag
Seit Jahresbeginn
1 Jahr
DYAI Moneyflow-Verteilung
DYAI Tägliches Leerverkaufsvolumen
DYAI Short-Interest-Historie
As of 2026-07-26, the Dyadic International, Inc. (DYAI) stock price today is 1.19. Based on this price, the company has a market capitalization of $43.36M, with a P/E ratio of --. On 2026-07-26, DYAI traded between 1.12 and 1.26. Today’s stock price is 6.25% above the daily low and 5.56% below the daily high, placing DYAI in der Mitte von its most recent trading range. Trading volume currently stands at 105.18K, compared with an average daily volume of 283.91K. This suggests that trading activity is deutlich unter dem üblichen Niveau than usual. Over the past year, Dyadic International, Inc. shares have traded between 0.65 and 1.60. At today’s price, DYAI is 83.08% above its 52-week low and 25.63% below its 52-week high.
Firmenname
Dyadic International, Inc.
Sektor
Health Services
Branche
Medical/Nursing Services
Börsen
Nasdaq
Anzahl der Beschäftigten
5
Losgröße
100
Offizielle Website
Währung
USD
Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.

DYAI FAQ